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A B S T R A C T
Background: Patients’ high adherence to medication is indispensable for the management of skin diseases
including atopic dermatitis. We previously showed poor medication adherence in Japanese
dermatological patients.
Objective: This study was conducted to determine the level of adherence to oral or topical medication in
Japanese patients with atopic dermatitis, attempting to characterize the socioeconomic status of those
patients with poor adherence.
Methods: A web questionnaire survey on demographic data as well as adherence level was conducted on
patients registered in the monitoring system. Adherence level was assessed with Morisky Medication
Adherence Scale-8 (MMAS-8). Among a total of 3096 respondents with dermatological disorders, data of
1327 subjects with atopic dermatitis were extracted and analyzed.
Results: More than 80% of subjects felt that both oral and topical medications were safe and efﬁcacious,
while less than 60% of them were satisﬁed with their treatment. Levels of adherence to oral and topical
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280 H. Murota et al. / Journal of Dermatological Science 79 (2015) 279–287treatments were evaluated with MMAS-8, giving scores of 4.6 and 4.2, respectively. Demographic factors
such as gender, marital status, state of employment, alcohol consumption, frequency of hospital visits,
and experience of drug effectiveness had a signiﬁcant impact on the degree of adherence to treatment.
Conclusion: Medication adherence level in Japanese subjects with atopic dermatitis was relatively low
compared with that of other chronic diseases. Our survey has characterized patients with poor
adherence, who are good targets for interventions to maximize potentially limited healthcare resources.
ã 2015 The Authors. Published by Elsevier Ireland Ltd on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
In the management of skin diseases, not only the prescription of
appropriate drugs by clinicians but also the enhancement of
patient adherence to medication is important. Recent studies
highlighted poor adherence to medication in patients with chronic
inﬂammatory diseases, such as hypertension, diabetes, and
inﬂammatory bowel diseases [1–3]. A low level of motivation to
adhere to medication has also been reported in patients with
atopic dermatitis [4], psoriasis [5], urticaria [6], and acne [7].Table 1
Demographic data of study subjects with atopic dermatitis (n = 1327).
Characteristics 
Age, mean (SD) [min–max], years 
Gender Male 
Female 
Marital state Married 
Unmarried 
Annual income 6 million yen 
<6 million yen 
Employment Employed 
Unemployed 
Education University graduate 
Not university graduate 
Smoking Smoker 
Non-smoker 
Alcohol Once a month 
<Once a month 
Frequency of hospital visits Once a half year 
<Once a half year or unkow
Main healthcare institution University hospital 
Municipal hospital 
Private clinic or other 
Oral medication Experience of drug effectiven
Experience of adverse event
Topical medication Experience of drug effectiven
Experience of adverse event
Overall satisfaction to treatment Satisﬁed 
<Satisﬁed 
Adherence, mean (SD) [min–max] Oral medication 
Topical medication 
Cronbach’s Alpha of adherance measure Oral medication 
Topical medication Previously, we assessed the adherence to oral and topical
medications using a translated Japanese version of Morisky
Medication Adherence Scale-8 (MMAS-8) in 3096 Japanese sub-
jects with skin diseases including atopic dermatitis, urticaria,
psoriasis, and tinea [8]. In that study, adherence level was classiﬁed
as high, medium, or low according to the MMAS-8 score [8]. We
found that the overall high, medium, and low adherence rates were
9.5%, 24.2%, and 66.3% for oral medication, and 6.9%, 17.7%, and
75.5% for topical medication, indicating poor adherence to
medication in patients with skin diseases. In the current study,n (%)
41.3 (11.1) [18–85]
559 42.1
768 57.9
597 45
730 55
411 37.1
696 62.9
877 69.4
387 30.6
670 50.6
653 49.4
227 17.2
1094 82.8
773 58.5
548 41.5
1226 92.4
n 101 7.6
58 4.4
216 16.4
1044 79.2
ess Yes 720 78.3
No 199 21.7
s Yes 163 17.7
No 756 82.3
ess Yes 1158 89.6
No 134 10.4
s Yes 247 19.1
No 1045 80.9
749 56.4
578 43.6
4.6 (2.0) [0–8]
4.2 (2.0) [0–8]
0.712
0.706
Table 2
Adherence levels by the type of medications among study subjects with atopic
dermatitis.
High Medium Low p-value
n (%) n (%) n (%)
Oral medication 74 181 664 0.030
(n = 919) (8.1) (19.7) (72.3)
Topical medication 76 223 993
(n = 1292) (5.9) (17.3) (76.9)
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characterize the socioeconomic status of patients with poor
adherence.
2. Material and methods
2.1. Setting and study population
This study was conducted among patients registered in a
monitoring system established by Macromill Inc., as previously
described [8]. In brief, a total of 3096 eligible patients [atopic
dermatitis (n = 1327), urticaria (n = 751), psoriasis (n = 237), or tinea
(n = 781)] were enrolled. Our web-based questionnaire included the
following items: age, sex, marital status, annual income, employ-
ment status, educational status, smoking habit, alcohol consump-
tion, frequency of hospital visits, main healthcare institution, oral or
topical medication, experience of effectiveness of oral or topical
medication, experience of adverse events associated with oral or
topical medication, overall satisfaction with treatment, and the
translated Japanese version of MMAS-8 for oral or topical
medication [8].
According to the MMAS-8 score (ranging from 0 to 8)
(Supplemental Fig. 1), adherence was categorized as high (score:
8), medium (score: 6, 7), or low (score: <6) [9].
2.2. Statistical analysis
Descriptive statistics were used to describe the demographics
and disease classiﬁcation of the patients and their medication
adherence scores, as previously described [8]. Proportions and
frequencies for categorical variables were calculated, while means
and standard deviations were calculated for continuous variables.
The characteristics of the whole sample and of the adherent groups
produced by the MMAS-8 score are presented. The chi square (x2)
test for categorical variables or analysis of variance (ANOVA) for
continuous variables was used to evaluate the difference of study
variables among the three adherence groups. Internal consistency
was assessed using Cronbach’s alpha. Known group validity was
assessed through the association of item and MMAS categories by
using correlation coefﬁcient and covariance. All analyses were
performed using STATA version 9. The signiﬁcance level was set at
p < 0.05.
3. Results
3.1. Presentation of patients’ demographics and treatment landscape
Table 1 summarizes the demographics and treatment land-
scape for all patients with atopic dermatitis (n = 1327). In terms of
the gender of the patients, 42.1% were male and 57.9% were female.
Demographic data, such as marital status, annual income level,
employment status, education level, and smoking and drinking
habits, were tallied. The current status of clinical visits was
assessed: 92.4% of the total subjects visited hospital more than
once every six months, and 79.2% of the total subjects consulted
private clinics. As for the treatment landscape, self-assessment of
both efﬁcacy and adverse events of medication was performed,
which revealed that more than 80% of the subjects felt that both
oral and topical medications were safe and efﬁcacious. However,
questions regarding their satisfaction with their treatment found
that only 56.4% of the subjects were satisﬁed. Adherence levels to
oral and topical treatments were scored with MMAS-8, which were
4.6 and 4.2, respectively. Reliability veriﬁcation with Cronbach's
alpha was performed. The values of consistency of MMAS-8 scoring
for oral and topical treatments were 0.712 and 0.705, respectively,indicating the validity of the translated Japanese version of MMAS-
8.
3.2. Level of adherence to treatment with oral and topical medications
Next, the level of adherence was compared between oral and
topical medications (Table 2). In those with oral medication, the
proportions of subjects in the high-, medium-, and low-adherence
groups were 8.1%, 19.7%, and 72.3%, respectively. In those with
topical medication, these proportions were 5.9%, 17.3%, and 76.9%,
respectively. When adherence scores were compared between oral
and topical medications, the adherence score to topical medication
was signiﬁcantly lower than that to oral medication (p = 0.03).
3.3. Difference of study variables among the three adherence levels
Next, the association of each variable with the adherence score
were assessed (Tables 3, 4). In terms of those with oral medication,
factors such as marital status, alcohol consumption, and experi-
ence of drug effectiveness had a signiﬁcant impact on the degree of
adherence to treatment (Table 3). Being married, alcohol
consumption less than once a month, and the experience of oral
drug effectiveness were factors associated with higher adherence
to oral medication (p < 0.001, p = 0.004, and p = 0.008, respectively)
(Table 3). When the subjects were divided along gender lines,
married male subjects had a high adherence level (Table 5,
Supplemental Tables 2, 3). The experience of adverse events
associated with taking oral medication did not affect the adherence
level (p = 0.999) (Table 3). In terms of those with topical
medication, factors such as gender, state of employment, and
frequency of hospital visits had a signiﬁcant impact on the degree
of adherence to treatment (Table 4). Male subjects, employed
individuals, and those visiting hospital more than once every six
months were factors associated with higher adherence to topical
medication (p = 0.002, p = 0.002, and p = 0.029, respectively)
(Table 4). Neither experience of drug effectiveness nor adverse
events affected the score of adherence to topical medication, with
statistical signiﬁcance (Table 4).
3.4. Barriers to higher medication adherence: from patients’
perspectives
To assess the barriers to higher medication adherence, we
investigated the reasons for discontinuing drug use without being
instructed to do so by a physician (Tables 6, 7). For oral medication,
forgetfulness (42.4%) and feeling better (39%) were the major
reasons for not taking medicines (Table 6). Although uncommon
overall, alcohol consumption was a reason for not taking medicines
in a relatively high percentage of subjects with atopic dermatitis or
tinea unguium (Table 6). For topical medication, messiness of
treatment (42.1%), forgetfulness (45.8%), and feeling better (35%)
were the major reasons for forgetting to take such medication
(Table 7). The rates of a shortage of drugs and feeling worse as
reasons for not taking medication were relatively high while the
rate of feeling that the drugs were ineffective was relatively low in
Table 3
Prevalence of study variables for the three adherence levels among study subjects with atopic dermatitis: oral medication (n = 919).
Characteristics High adherence Medium adherence Low adherence p-value
n = 74 (8.1%) n = 181 (19.7%) n = 664 (72.3%)
Age, mean (SD), years 40.2 (10.3) 43.6 (11.2) 40.8 (10.9) 0.008
Gender n (%) Male 37 86 284 0.307
(9.1) (21.1) (69.8)
Female 37 95 380
(7.2) (18.6) (74.2)
Marital status n (%) Married 51 87 290 <0.001
(11.9) (20.3) (67.8)
Unmarried 23 94 374
(4.7) (19.1) (76.2)
Annual income n (%) 6 million yen 23 62 199 0.603
(8.1) (21.8) (70.1)
<6 million yen 38 89 345
(8.1) (18.9) (73.1)
Employment n (%) Employed 55 123 443 0.235
(8.9) (19.8) (71.3)
Unemployed 16 42 192
(6.4) (16.8) (76.8)
Education n (%) University graduate 33 92 340 0.541
(7.1) (19.8) (73.1)
Not university graduate 41 88 322
(9.1) (19.5) (71.4)
Smoking n (%) Smoker 13 30 123 0.828
(7.8) (18.1) (74.1)
Non-smoker 61 150 538
(8.1) (20.0) (71.8)
Alcohol n (%) Once a month 34 96 414 0.004
(6.3) (17.6) (76.1)
<Once a month 40 84 247
(10.8) (22.6) (66.6)
Frequency of hospital visits n (%) Once a half year 71 173 624 0.691a
(8.2) (19.9) (71.9)
< Once a half year or unkown 3 8 40
(5.9) (15.7) (78.4)
Main healthcare institution n (%) University hospital 5 13 30 0.059a
(10.4) (27.1) (62.5)
Municipal hospital 18 33 99
(12.0) (22.0) (66.0)
Private clinic or other 49 133 532
(6.9) (18.6) (74.5)
Experience of drug effectiveness n (%) Yes 66 150 504 0.008
(9.2) (20.8) (70.0)
No 8 31 160
(4.0) (15.6) (80.4)
Experience of adverse events n (%) Yes 13 32 118 0.999
(8.0) (19.6) (72.4)
No 61 149 546
(8.1) (19.7) (72.2)
Overall satisfaction to treatment n (%) Satisﬁed 46 114 365 0.102
(8.8) (21.7) (69.5)
<Satisﬁed 28 67 299
(7.1) (17.0) (75.9)
a Fisher’s exact test.
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(Table 7).
4. Discussion
In this study, the actual medication adherence levels of
Japanese patients with atopic dermatitis and their reasons fordrug discontinuation were examined. This is the ﬁrst study
characterizing patients with atopic dermatitis using MMAS-8.
Previously, overall adherence levels in Japanese dermatological
patients were compared among atopic dermatitis, urticaria,
psoriasis, and tinea [8]. The results showed a signiﬁcantly lower
level of adherence to oral medication in subjects with atopic
dermatitis than in other diseases [8]. Atopic dermatitis severely
Table 4
Prevalence of study variables for the three adherence levels among study subjects with atopic dermatitis: Topical medication (n = 1292).
Characteristics High adherence Medium adherence Low adherence p-value
n = 76 (5.9%) n = 223 (17.3%) n = 993 (76.9%)
Age, mean (SD), years 42.2 (9.5) 42.2 (12.3) 41.0 (10.9) 0.225
Gender n (%) Male 38 114 391 0.002
(7.0) (21.0) (72.0)
Female 38 109 602
(5.1) (14.6) (80.4)
Marital status n (%) Married 35 114 433 0.123
(6.0) (19.6) (74.4)
Unmarried 41 109 560
(5.8) (15.4) (78.9)
Annual income n (%) 6 million yen 26 67 309 0.785
(6.5) (16.7) (76.9)
<6 million yen 41 124 514
(6.0) (18.3) (75.7)
Employment n (%) Employed 64 144 644 0.002
(7.5) (16.9) (75.6)
Unemployed 9 69 299
(2.4) (18.3) (79.3)
Education n (%) University graduate 37 116 504 0.880
(5.6) (17.7) (76.7)
Not university graduate 39 107 485
(6.2) (17.0) (76.9)
Smoking n (%) Smoker 11 36 171 0.766
(5.1) (16.5) (78.4)
Non-smoker 65 187 816
(6.1) (17.5) (76.4)
Alcohol n (%) Once a month 39 128 584 0.386
(5.2) (17.0) (77.8)
<Once a month 37 95 403
(6.9) (17.8) (75.3)
Frequency of hospital visits n (%) Once a half year 72 215 908 0.029
(6.0) (18.0) (76.0)
<Once half year or unkown 4 8 85
(4.1) (8.3) (87.6)
Main healthcare institution n (%) University hospital 4 9 43 0.489a
(7.1) (16.1) (76.8)
Municipal hospital 11 45 154
(5.2) (21.4) (73.3)
Private clinic or other 61 167 789
(6.0) (16.4) (77.6)
Experience of drug effectiveness n (%) Yes 72 204 882 0.161
(6.2) (17.6) (76.2)
No 4 19 111
(3.0) (14.2) (82.8)
Experience of adverse events n (%) Yes 11 42 194 0.553
(4.5) (17.0) (78.5)
No 65 181 799
(6.2) (17.3) (76.5)
Overall satisfaction to treatment n (%) Satisﬁed 52 124 548 0.080
(7.2) (17.1) (75.7)
<Satisﬁed 24 99 445
(4.2) (17.4) (78.4)
a Fisher’s exact test.
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patients’ motivation to take medication is very important because
it will improve their quality of life and their productivity and thus
increase socioeconomic activity. In the present study, mean
MMAS-8 scores for oral and topical medications were 4.6 and
4.2, respectively (Table 1). The MMAS-8 score for oral medicationwas lower than that for psoriasis (5.2), another common type of
chronic dermatitis, while the topical score was comparable to that
of psoriasis (4.3) [8,11]. Mean MMAS-8 scores for other chronic
diseases such as osteoporosis and asthma were 6.2 and 5.4,
respectively [12,13]. Our ﬁrst attempt to assess adherence in cases
of atopic dermatitis by using MMAS-8 has clearly shown that the
Table 5
Prevalence of marital status for the three adherence levels devided along gender lines.
Gender Characteristics High adherence n (%) Medium adherence n (%) Low adherence n (%) p-value
Male Oral medication 37 (9.1) 86 (21.1) 284 (69.8)
Married 29 (15.5) 38 (20.3) 120 (64.2) <0.001
Unmarried 8 (3.6) 48 (21.8) 164 (74.6)
Topical medication 38 (7.0) 114 (21.0) 391 (72.0)
Married 21 (8.4) 59 (23.7) 169 (67.9) 0.132
Unmarried 17 (5.8) 55 (18.7) 222 (75.5)
Female Oral medication 37 (7.2) 95 (18.6) 380 (74.2)
Married 22 (9.1) 49 (20.3) 170 (70.5) 0.143
Unmarried 15 (5.5) 46 (17) 210 (77.5)
Topical medication 38 (5.1) 109 (14.6) 602 (80.4)
Married 14 (4.2) 55 (6.5) 264 (79.3) 0.277
Unmarried 24 (5.8) 54 (13.0) 338 (81.3)
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poor for both oral and topical medications. There is some evidence
to support this ﬁnding. Krejci-Manwaring et al. reported poor
adherence to topical medication in children with atopic dermatitis
[14]. Moreover, Feldman et al. reported that the level of adherence
to topical medication in an atopic dermatitis group was lower than
that in a psoriasis group or a hand dermatitis group [15]. In these
previous studies, adherence to topical medication was high around
the time of ofﬁce visits, but rapidly decreased soon after [14,15].
Thus, the most important issue here is how to offer effective
motivation for using medication, ensuring that patients visit
hospitals sufﬁciently often.
Demographic/clinical information related to a lower adher-
ence level might provide a helpful perspective to grasp the
characteristics of patients who need special attention. Wilke et al.
assessed the adherence level in German patients with medica-
tion, revealing that being relatively young, having chronic disease,
and number of medications to be taken were factors explaining
non-adherence [16]. In the ﬁeld of dermatology, Richmond et al.,
who assessed the adherence level of new patients in a
dermatology clinic at the University of Miami, reported that
the reasons for poor adherence to medication were lack of time
and poor insurance coverage for medication [17]. From the results
of our study, marital status, alcohol consumption, and experience
of drug effectiveness had an inﬂuence on the level of adherence to
oral medication (Table 3). On the other hand, factors such as
gender, employment status, and frequency of hospital visits had a
large impact on the level of adherence to topical medication
(Table 4). Interestingly, the factors affecting adherence differed
between oral and topical medications. Marital status inﬂuenced
oral medication adherence, but not that for topical medication.
Moreover, being married and male was a factor related to a higher
adherence level for oral medication (Table 5), suggesting the
favorable effects of distinctive living environment of married
individuals on their adherence to oral medication. We can
imagine some conceivable living environment affecting adher-
ence. It assumed that married men might be encouraged to take
oral medication by their wives. Therewith, they may be supported
to lead a well balanced and regulated life. Married male may also
have a higher interest in his own health from a sense of
responsibility to maintain his family [18]. Indeed, association of
marital status and cancer screening participation has been
reported [19,20]. Alternatively, the unmarried group may have
included more young people, who usually show lower adherence
[8]. To verify this hypothesis, we examined married and
unmarried subjects separately (Supplemental Tables 4 and 5).To our surprise, mean age was higher in unmarried subjects than
in married ones. Thus, being married was a beneﬁcial factor for
oral medication adherence in males with atopic dermatitis, which
was not related to their age. Similarly, unmarried patients were
reported to be at high risk of non-adherence to medication in
cases of heart failure and hypertension [21,22]. In contrast, being
married negatively inﬂuenced adherence to medication in cases
of gastroesophageal reﬂux disease [23] or had no impact on
adherence in those with chronic obstructive pulmonary disease
[24] and rheumatoid arthritis [25]. In our previous assessment of
all dermatological diseases, marital status had no inﬂuence on the
level of adherence to both oral and topical medications [8].
Although the impact of marital status on medication adherence
varies among different diseases, this demographic factor may be
important for determining adherence levels in atopic dermatitis.
We currently do not know why married status showed beneﬁcial
impacts only on patients with AD, but not on those with other
skin diseases. We could only speculate that different tempera-
ments of patients with different diseases (at least for AD, psoriasis
and urticaria) [26] might possibly cause such a difference. Gender
and employment status were factors inﬂuencing topical medica-
tion adherence, which was unique to atopic dermatitis (Table 4)
[8,11]. Patients drinking alcohol less than once a month showed a
higher adherence to oral medication than those who drank more.
Doctors often advise the patients not to take oral medicine with
alcohol. Some patients may refrain from taking medicine instead
of stopping drinking. Indeed, alcohol consumption was a reason
for not taking medicines in a relatively high percentage of
subjects with atopic dermatitis (Table 6). In subjects with atopic
dermatitis, experience of drug effectiveness contributed to high
adherence levels for oral medication, while a low frequency of
hospital visits was associated with poor adherence to topical
medication (Tables 3, 4). These items were not among the factors
inﬂuencing the levels of adherence to oral or topical medication
in Japanese subjects with psoriasis [8,11], indicating that these
items can also be unique inﬂuential factors in atopic dermatitis.
Experience of the effectiveness of oral medication may well
generate a high motivation to maintain treatment. Regarding
hospital visits, it may be natural that patients with low adherence
go to see doctors less frequently. We should take advantage of the
high rate of topical treatment adherence on and near days of
clinical visits [14,15] in order to increase motivation to maintain
medication use and ensure good control of the disease.
To improve low adherence to medication, it is important to
determine the reasons why patients discontinue the use of drugs. In
our study, messiness of drug use, forgetfulness, and self-assessment
Table 7
Reasons for discontinuing the topical drug without directions from a physician (multiple answers allowed).
Disease n Messiness of
treatment
Forgetfulness Being
busy
Too high
frequency of use
Too many different
medications
Feeling drugs
were ineffective
Shortage
of drugs
Inaccessible
locations
Feeling
better
Feeling
sick
Feeling
worse
Concern about
side effects
Other
689 45.3 49.2 23.8 12 2.6 9.7 15.1 9.3 32.9 6.8 2.5 8.9 6.8
Atopic
dermatitis
349 42.1 45.8 26.6 14.3 2.9 5.7 18.6 9.7 35 8.6 3.4 10.9 8.3
Urticaria 124 36.3 47.6 14.5 7.3 2.4 16.1 16.1 8.1 29 8.9 2.4 10.5 8.1
Psoriasis 73 56.2 47.9 27.4 11 6.8 9.6 12.3 16.4 32.9 2.7 0 11 5.5
Tinea pedis 76 57.9 56.6 27.6 9.2 0 11.8 7.9 5.3 40.8 5.3 0 2.6 1.3
Tinea
unguium
67 52.2 62.7 17.9 13.4 0 16.4 6 6 20.9 0 3 0 4.5
Gray column shows the number of cases. Figures in the other columns show the percentage relative to total number of cases with each disease.
Table 6
Reasons for discontinuing oral drug without directions from a physician (multiple answers allowed).
Disease n Messiness of
treatment
Forgetfulness Being
busy
Alcohol
consumption
Feeling drugs
were ineffective
Shortage of
drugs
Skipping a
meal
Difﬁculty of
taking drugs (size,
form, and taste)
Feeling
better
Feeling
sick
Concern about
side effects
Other
286 22.7 39.9 14.7 8.4 15.7 12.2 7.3 2.8 38.8 2.4 15.4 11.5
Atopic
dermatitis
177 22.6 42.4 16.9 11.3 16.9 13.6 8.5 2.8 39 2.8 15.3 6.8
Urticaria 75 18.7 33.3 10.7 2.7 13.3 10.7 5.3 2.7 48 1.3 14.7 18.7
Psoriasis 13 23.1 30.8 15.4 0 23.1 15.4 7.7 0 30.8 7.7 15.4 23.1
Tinea pedis 14 50 42.9 14.3 7.1 7.1 0 0 7.1 7.1 0 14.3 14.3
Tinea unguium 7 14.3 57.1 0 14.3 14.3 14.3 14.3 0 14.3 0 28.6 28.6
Gray column shows the number of cases. Figures in the other columns show the percentage relative to total number of cases with each disease.
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discontinuation (Tables 6, 7). Similar results were reported from a
Spanish survey on the adherence levels of subjects with atopic
dermatitis [4]. In this report, most patients discontinued treatment
when their symptoms subsided. Moreover, they occasionally forgot
to use topical medicines[4]. Such trendsshould beremediedbecause
subclinical inﬂammation in a treated area that cannot be detected by
the patient is related to repeated recurrence of this disease and
maintenance therapy has been considered important to prevent
recurrence [27]. Thus, advising patients to continue topical
treatment even after they think their skin lesions have cleared up
is regarded helpful to avoid recurrence. The reason for not using
medicines of a shortage of drugs was relatively common and the
feeling that their drugs were ineffective was relatively uncommon in
atopic dermatitis compared with those in the other skin diseases
(Table 7). It is thus also important to encourage patients to visit
hospital before they run out of drugs.
The contents of the explanations by the patients’ doctors were
also examined (Supplemental Table 6). We found that many
patients with atopic dermatitis received an insufﬁcient explana-
tion about both the nature of the disease and the required therapy
duration compared with those with other skin diseases. By
contrast, more patients with atopic dermatitis received an
explanation about factors that could exacerbate their condition
and the importance of an adequate diet and lifestyle improvement.
Medical staff should attempt to give patients clear goals in each
therapeutic phase and an indication of the likely therapeutic
duration.
There were some limitations in our study. We did not meet the
patients in person and conﬁrm the self-reported diagnosis. In
addition, besides the limited number of study subjects, disease
severity and presence of complications were not considered in this
survey. The severity of dermatitis would inﬂuence the adherence.
Improving adherence levels will make skin condition better, which,
in turn, may induce a better adherence. Although this virtuous
circle should be pursued, there are not enough data for discussion
in this study. There is also a risk of population bias because this
study is based on an internet survey. Nevertheless, we believe that
the results provided by our survey contain valuable information for
the management of atopic dermatitis. We have clariﬁed the
socioeconomic status of patients showing poor medical adherence
and the reasons for drug discontinuation, which is useful to ﬁnd
good targets for intervention and to make the best use of
potentially limited healthcare resources.
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